Overlooked ‘off switch’ in lung tumors may explain why immunotherapy doesn't work for everyone (IMAGE)
Caption
New research shows that human lung cancers use a process called alternative RNA splicing to produce different versions (isoforms) of the immune-alarm gene STAT2, shown here as ribbons. Isoforms of STAT2 are associated with how well lung cancer patients respond to immunotherapy: an isoform that retains an extra segment called an intron (top ribbon) is found in patients who respond to anti-PD-L1, while an isoform without it (bottom ribbon) is found in non-responders. These splicing signatures could one day help doctors predict, before treatment begins, which patients are most likely to benefit from immunotherapy.
Credit
The Jackson Laboratory
Usage Restrictions
none
License
Original content